Axitinib
Information
- Drug Name
- Axitinib
- Description
- Entry(CIViC)
- 29
CIViC
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.Leu267Val (p.L267V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu267Val (p.L267V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.Gly269Glu (p.G269E) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gly269Glu (p.G269E) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.Gln271His (p.Q271H) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gln271His (p.Q271H) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.Tyr272Phe (p.Y272F) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Tyr272Phe (p.Y272F) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.Asp295Gly (p.D295G) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Asp295Gly (p.D295G) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this study, enzymatic profiling, crystal struct... | ABL1 | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | Sensitivity | true | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 | ABL1 p.Phe336Leu (p.F336L) ABL1 p.Phe336Leu (p.F336L) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.His415Arg (p.H415R) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.His415Arg (p.H415R) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 | ABL1 p.Phe505Ser (p.F505S) ABL1 p.Phe505Ser (p.F505S) | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.Leu403Met (p.L403M) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu403Met (p.L403M) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.Phe378Ile (p.F378I) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Ile (p.F378I) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.Met362Thr (p.M362T) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met362Thr (p.M362T) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.Phe336Val (p.F336V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe336Val (p.F336V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 | ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V | Sensitivity | true | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.Val318Leu (p.V318L) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Val318Leu (p.V318L) ( ENST00000318560.6, ENST00000372348.9 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.Thr334Ala (p.T334A) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Thr334Ala (p.T334A) ( ENST00000318560.6, ENST00000372348.9 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.Met370Thr (p.M370T) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met370Thr (p.M370T) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.His415Pro (p.H415P) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.His415Pro (p.H415P) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 | ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V | Sensitivity | true | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 | ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 | ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 | ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a proliferation assay measuring tritiated thymi... | ABL1 |
ABL1 p.Leu267Arg (p.L267R) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu267Arg (p.L267R) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Bone marrow mononuclear cells (BM MNCs) were isola... | ABL1 | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02535533 | Active, not recruiting | Phase 1/Phase 2 | SLM + Axitinib for Clear Cell RCC | January 2016 | May 17, 2026 |
| NCT03595124 | Active, not recruiting | Phase 2 | A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) | January 8, 2019 | September 30, 2027 |
| NCT05059522 | Active, not recruiting | Phase 3 | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | September 29, 2021 | September 30, 2026 |
| NCT04337970 | Active, not recruiting | Phase 1/Phase 2 | Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer | April 6, 2020 | October 2024 |
| NCT04585815 | Active, not recruiting | Phase 1/Phase 2 | Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) | November 10, 2020 | June 17, 2024 |
| NCT03172754 | Active, not recruiting | Phase 1/Phase 2 | Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma | June 12, 2017 | April 6, 2025 |
| NCT01409200 | Active, not recruiting | Phase 2 | Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis | March 26, 2012 | June 30, 2025 |
| NCT05097599 | Active, not recruiting | Phase 2 | Strata PATH™ (Precision Indications for Approved Therapies) | November 19, 2021 | November 19, 2029 |
| NCT04562441 | Active, not recruiting | Phase 2 | NPC - AXEL Study : Axitinib-Avelumab | May 6, 2021 | December 31, 2027 |
| NCT04493203 | Active, not recruiting | Phase 2 | Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma | December 18, 2020 | February 28, 2029 |
| NCT03092856 | Active, not recruiting | Phase 2 | Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer | July 19, 2017 | July 19, 2025 |
| NCT05017012 | Active, not recruiting | Phase 1 | A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18) | September 21, 2021 | September 26, 2026 |
| NCT02853331 | Active, not recruiting | Phase 3 | Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) | September 16, 2016 | December 31, 2025 |
| NCT03826589 | Active, not recruiting | N/A | Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy | June 1, 2019 | July 1, 2024 |
| NCT04458259 | Active, not recruiting | Phase 1 | Study of PF-07265807 in Participants With Metastatic Solid Tumors. | September 24, 2020 | June 30, 2024 |
| NCT02912572 | Active, not recruiting | Phase 2 | Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer | November 14, 2016 | March 2027 |
| NCT01486251 | Completed | N/A | Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer | September 2011 | September 2014 |
| NCT01490866 | Completed | Phase 2 | A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) | January 2012 | July 2015 |
| NCT01529138 | Completed | Phase 1 | Study of Axitinib and Temsirolimus in Solid Tumors | October 2011 | March 2014 |
| NCT01540526 | Completed | Phase 1 | Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib | March 2012 | December 2014 |
| NCT01562197 | Completed | Phase 2 | A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma | April 2014 | December 2018 |
| NCT00094094 | Completed | Phase 2 | Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer | February 2005 | July 2007 |
| NCT01798446 | Completed | Phase 2 | A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus | February 2013 | December 2016 |
| NCT01999972 | Completed | Phase 1 | A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors | February 26, 2014 | September 5, 2019 |
| NCT02129647 | Completed | Phase 2 | Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas | April 2014 | February 5, 2019 |
| NCT02133742 | Completed | Phase 1 | A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer | September 16, 2014 | July 3, 2019 |
| NCT02156895 | Completed | Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea | July 17, 2018 | August 6, 2021 | |
| NCT02164838 | Completed | Phase 1 | VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors | September 2014 | October 19, 2017 |
| NCT02261207 | Completed | Phase 2 | Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor | November 2014 | March 2018 |
| NCT02489695 | Completed | Phase 2 | Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma | October 2015 | July 2019 |
| NCT02579811 | Completed | Phase 2 | Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer | December 30, 2015 | June 20, 2023 |
| NCT02597322 | Completed | Phase 2 | Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN) | February 2012 | June 2017 |
| NCT02636725 | Completed | Phase 2 | Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas | April 19, 2016 | March 3, 2023 |
| NCT02639182 | Completed | Phase 2 | A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma | May 3, 2016 | October 2, 2020 |
| NCT02667886 | Completed | Phase 1/Phase 2 | Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma | January 2016 | March 2022 |
| NCT02700568 | Completed | Phase 2 | Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors | January 2016 | August 2018 |
| NCT02762513 | Completed | Phase 2 | Expansion Trial for Axitinib In Head And Neck Cancer | August 30, 2016 | April 9, 2020 |
| NCT02814461 | Completed | Phase 1 | The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC | November 2015 | November 2018 |
| NCT02857712 | Completed | Phase 2 | Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14 | December 2014 | January 2019 |
| NCT02859012 | Completed | Phase 2 | Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma | September 2016 | August 2020 |
| NCT01693822 | Completed | Phase 2 | A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy | October 2012 | February 28, 2022 |
| NCT00700258 | Completed | Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] | February 13, 2008 | December 28, 2021 | |
| NCT00768755 | Completed | Phase 1/Phase 2 | Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer | January 2009 | March 2012 |
| NCT00828919 | Completed | N/A | Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials | March 7, 2003 | August 14, 2023 |
| NCT00835978 | Completed | Phase 2 | Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer | August 2009 | February 2016 |
| NCT00842244 | Completed | Phase 1 | Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer | April 2009 | October 2012 |
| NCT01140737 | Completed | Phase 2 | A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas | August 31, 2010 | January 8, 2019 |
| NCT01174238 | Completed | Phase 2 | A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma | July 2010 | December 2013 |
| NCT01211275 | Completed | Phase 1/Phase 2 | Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma | May 22, 2009 | May 6, 2013 |
| NCT01249547 | Completed | Phase 2 | Nasopharyngeal Carcinoma (NPC) Axitinib | December 2010 | December 2016 |
| NCT01255137 | Completed | Phase 2 | Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer | September 2010 | December 2012 |
| NCT01263769 | Completed | Phase 2 | Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC) | February 2011 | June 5, 2023 |
| NCT01321437 | Completed | Phase 2 | Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma | December 2011 | December 2016 |
| NCT01352728 | Completed | Phase 2 | Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib | May 18, 2011 | June 7, 2018 |
| NCT01385059 | Completed | Phase 2 | Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer | October 28, 2011 | October 9, 2013 |
| NCT01435122 | Completed | Phase 2 | A Study of Axitinib in Advanced Carcinoid Tumors | October 25, 2011 | February 13, 2018 |
| NCT03291314 | Completed | Phase 2 | Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma | May 3, 2017 | January 1, 2019 |
| NCT03990571 | Completed | Phase 2 | Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | July 22, 2019 | March 20, 2023 |
| NCT04033991 | Completed | Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib. | September 27, 2019 | December 18, 2020 | |
| NCT04118855 | Completed | Phase 2 | Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma | March 1, 2020 | March 31, 2023 |
| NCT04355156 | Completed | Phase 2 | Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal Cancer | September 17, 2012 | February 22, 2019 |
| NCT04540705 | Completed | Phase 1 | A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread | September 11, 2020 | January 18, 2024 |
| NCT04637204 | Completed | Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England | November 24, 2020 | December 11, 2020 | |
| NCT04669366 | Completed | Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries | January 20, 2021 | July 31, 2021 | |
| NCT04682587 | Completed | To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma | February 24, 2021 | April 5, 2021 | |
| NCT05012865 | Completed | Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART) | September 14, 2021 | January 31, 2022 | |
| NCT05394493 | Completed | An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK | June 11, 2021 | August 30, 2023 | |
| NCT05650164 | Completed | Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2) | January 25, 2023 | October 13, 2023 | |
| NCT05904730 | Enrolling by invitation | Phase 1 | Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations | July 11, 2023 | November 9, 2024 |
| NCT02354612 | No longer available | Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial | |||
| NCT01473043 | No longer available | Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment | March 2012 | March 2014 | |
| NCT05808608 | Not yet recruiting | Phase 1/Phase 2 | A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma | September 2023 | December 2025 |
| NCT04958473 | Not yet recruiting | Phase 2 | A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer | August 1, 2021 | August 1, 2025 |
| NCT06211114 | Not yet recruiting | Phase 2 | Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma | February 2024 | February 2027 |
| NCT06161558 | Not yet recruiting | Phase 1 | Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors | June 23, 2024 | November 16, 2027 |
| NCT06279403 | Not yet recruiting | Phase 2 | Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma | March 1, 2024 | March 1, 2029 |
| NCT04522323 | Recruiting | Phase 1 | A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma | August 5, 2020 | August 4, 2027 |
| NCT04341181 | Recruiting | Phase 2 | ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling | August 24, 2020 | April 30, 2025 |
| NCT05817903 | Recruiting | Phase 2 | Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients | April 18, 2023 | April 1, 2027 |
| NCT05805501 | Recruiting | Phase 2 | A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma | April 21, 2023 | March 31, 2026 |
| NCT05949632 | Recruiting | Phase 1/Phase 2 | A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors | April 16, 2024 | December 15, 2027 |
| NCT05969496 | Recruiting | Phase 2 | Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus | December 4, 2023 | November 2029 |
| NCT04693468 | Recruiting | Phase 1 | Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial | December 1, 2020 | September 3, 2025 |
| NCT04996823 | Recruiting | Phase 2 | Axitinib + Ipilimumab in Advanced Melanoma | August 4, 2021 | August 2027 |
| NCT05256472 | Recruiting | Phase 2 | A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma | July 6, 2023 | December 31, 2025 |
| NCT05327686 | Recruiting | Phase 2 | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study | June 30, 2022 | June 15, 2032 |
| NCT05363631 | Recruiting | Phase 1/Phase 2 | Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab | September 19, 2022 | December 31, 2026 |
| NCT05384496 | Recruiting | Phase 2 | Axitinib and Nivolumab for the Treatment of Mucosal Melanoma | May 17, 2022 | May 2026 |
| NCT05420220 | Recruiting | Phase 2 | Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer | July 15, 2022 | December 26, 2027 |
| NCT02925234 | Recruiting | Phase 2 | The Drug Rediscovery Protocol (DRUP Trial) | August 2016 | December 2027 |
| NCT06364631 | Recruiting | Phase 3 | CARE1 Pragmatic Clinical Trial | April 12, 2024 | May 5, 2032 |
| NCT03297606 | Recruiting | Phase 2 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | March 23, 2018 | January 31, 2027 |
| NCT03341845 | Recruiting | Phase 2 | Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC | March 28, 2018 | January 31, 2025 |
| NCT03839498 | Recruiting | Phase 2 | Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma | January 22, 2019 | January 2024 |
| NCT05768464 | Recruiting | Phase 2 | Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors | February 1, 2023 | December 30, 2027 |
| NCT01483638 | Terminated | Phase 2 | Axitinib as Maintenance Treatment in Patients With Metastatic CRC | February 2012 | September 2015 |
| NCT01599754 | Terminated | Phase 3 | Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients | April 2012 | May 2018 |
| NCT01533948 | Terminated | Phase 2 | Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery | January 2012 | July 2015 |
| NCT02560012 | Terminated | Phase 2 | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | January 4, 2016 | July 27, 2017 |
| NCT01649180 | Terminated | Phase 2 | NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma | July 2012 | March 2016 |
| NCT03386929 | Terminated | Phase 1/Phase 2 | Survival Prolongation by Rationale Innovative Genomics | November 29, 2017 | December 29, 2022 |
| NCT01508117 | Terminated | Phase 2 | Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients | August 2011 | October 2012 |
| NCT01806064 | Terminated | Phase 1/Phase 2 | Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma | March 8, 2013 | June 12, 2019 |
| NCT05249569 | Terminated | Phase 2 | Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma | November 4, 2022 | December 30, 2022 |
| NCT02782403 | Terminated | Phase 1 | Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia | March 20, 2017 | November 11, 2019 |
| NCT05070221 | Unknown status | Phase 1 | Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis | October 1, 2021 | December 31, 2023 |
| NCT04995016 | Unknown status | Phase 2 | Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma | August 20, 2021 | August 20, 2023 |
| NCT04258956 | Unknown status | Phase 2 | A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy | April 30, 2019 | April 30, 2023 |
| NCT04385654 | Unknown status | Phase 2 | Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma | June 2020 | June 2022 |
| NCT02638428 | Unknown status | Phase 2 | Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | December 2015 | December 2023 |
| NCT01744249 | Unknown status | Phase 2/Phase 3 | Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas | November 2011 | October 2021 |
| NCT05176288 | Withdrawn | Phase 2 | Avelumab, Palbociclib and Axitinib in Advanced RCC | May 31, 2024 | August 31, 2027 |
| NCT05263609 | Withdrawn | Phase 2 | Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib | June 2022 | June 2027 |
| NCT03481842 | Withdrawn | Phase 1/Phase 2 | Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis | October 10, 2021 | October 10, 2021 |
| NCT04197219 | Withdrawn | Phase 2 | Pembrolizumab With Axitinib in Recurrent Endometrial Cancer | February 1, 2021 | December 1, 2026 |
- Trade name (Drug list of Screening Committee of Anticancer Drugs)
- Inlyta
- US Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2012
- Japan Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2012
- Target (Drug list of Screening Committee of Anticancer Drugs)
- Multi-kinases
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 腎細胞がん